Status:
UNKNOWN
The Safety and Efficacy of Peri-procedure Blood Pressure Management of Revascularization
Lead Sponsor:
Xuanwu Hospital, Beijing
Collaborating Sponsors:
Beijing Tiantan Hospital
Peking University Third Hospital
Conditions:
Cerebral Revascularization
Ischemic Cerebrovascular Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Objective: Referring The relation between CEA(Carotid endarterectomy) postoperative blood flow monitoring and blood pressure, and combining patient demographics and preoperative risk factors to establ...
Eligibility Criteria
Inclusion
- symptomatic patient with carotid artery stenosis\>=50% or asymptomatic patient with carotid artery stenosis\>=70%, according to DSA or CTA;
- without massive cerebral infarction(infarction area \>1/2 territory of middle cerebral artery) confirmed by CT or MRI;
- informed consent acquired.
Exclusion
- lesion beyond range limit of procedure (higher than C2);
- target vascular complete occlusion or ipsilateral intracranial artery severe stenosis or complete occlusion cannot be revascularized via CEA procedure
- nonatherosclerotic carotid stenosis, such as vasculitis, dissection, congenital vascular malformation;
- history of instable angina pectoris, myocardial infarction or congestive heart failure within 6 months unable to accept systematic anesthesia;
- history of severe injury, surgery or radiotherapy on neck;
- with comorbid hemorrhagic cerebral disease such as intracranial aneurysm or vascular malformation;
- with comorbid blood system disease causing refractory coagulation dysfunction or rejection to blood or blood products perfusion;
- with other comorbidity, expected life \< 2 years;
- severe diabetes mellitus difficult to control, blood sugar \>300mg/dl;
- pregnancy or peri-natal period;
- intolerance to systematic anesthesia or surgery after adequate preparation.
- intolerance to peri-procedural drug possible to administrated;
- not cooperating or rejecting to informed consent;
Key Trial Info
Start Date :
April 10 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2019
Estimated Enrollment :
2270 Patients enrolled
Trial Details
Trial ID
NCT03256513
Start Date
April 10 2017
End Date
June 1 2019
Last Update
August 22 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of neurosurgery, Xuanwu hospital
Beijing, China, 100053